Piramal Enterprises Limited (PEL) is one of India’s large companies, with a presence in Financial Services and Pharmaceuticals. PEL’s consolidated revenues were ~$ 1.9 Billion in FY 2022, with 39% of revenues generated from outside India.

Read More
Highlights of the Company

`13,993 Cr

Revenues for FY 2022

`1,999 Cr

Net Profit for FY 2022


Total Employees

Acquired DHFL

Progressing on Pharma demerger


Our Board approved the demerger of our Pharma business and the simplification of the corporate structure in October 2021, transforming our company from a multi-sector conglomerate structure into two separate sector-focused listed entities in Financial Services and Pharmaceuticals. We are on-track and the demerger is expected to get completed by the Q3 FY 2023, subject to various required approvals.

With the DHFL integration now largely complete, we are focused on achieving sustained growth and profitability. We are working towards further diversifying our financial services business model to make it retail oriented, while achieving a balance between three pillars - Growth, Risk and Profitability.

Within Pharma, we have demonstrated consistent execution against key strategic priorities and are in the process of executing on our investment plans. Our global footprint with a diversified revenue base, presence in attractive segments with high entry barriers, our capability to meet a wide range of customer requirements across multiple geographies and best-in-class quality track record, provides greater stability from a longterm investment perspective.

Ajay G. Piramal


Read More


PEL to become listed NBFC post demerger of
pharma business

PEL will be a large diversified listed NBFC, with significant presence across both retail and wholesale financing

Read more

PPL will be a large India-listed
pharma company

PPL will be a large India-listed Pharma company, focused on Contract Development and Manufacturing, Complex Hospital Generics and India Consumer Healthcare

Read more

Transformed and strengthened
the company

The DHFL acquisition created one of the leading NBFCs in India, focused on affordable housing and MSME lending

Read more

Demerger of the pharma business and corporate structure simplification

Transforming from a multi-sector conglomerate structure into separate sector-focused listed entities in Financial Services and Pharmaceuticals

Read more


Retail Lending

Multi-product retail lending platform, ‘digital-at-the-core’ DHFL acquisition significantly increased the size and scale of the retail lending business

Wholesale Lending

Loans to residential & commercial real estate developers, as well as, corporates in select sectors

Alternative AUM

Fund management business; partnerships with marquee investors such as CDPQ and Bain Capital Credit

Life Insurance

JV with Prudential International Insurance Holdings; industry leader in the Defense segment

Investments in Shriram

20% stake in SCL2
~10% stake in SCUF2

Contract Development and Manufacturing Organisation (CDMO)

API and formulation manufacturing with a presence across the drug lifecycle, including research, development, clinical, and commercial manufacture.

Complex Hospital Generics

Portfolio of inhalation anaesthesia, injectable anaesthesia and pain management, injectable intrathecal treatment, and other injectables products sold across the globe.

India Consumer Healthcare

India Consumer healthcare business in India with a portfolio of multiple brands in attractive segments and a nationwide sales & marketing infrastructure

JV with Allergan
(49% stake)

A market leader in the fastgrowing ophthalmology category in India, offering medications for diseases like glaucoma, dry eye, infections, and inflammations.

Risk Management

A well-defined risk management framework is integral to any business, but is especially important during times of uncertainty. The outbreak of COVID-19 in 2020, and its resurgence has prolonged macro-economic uncertainty.

Read more


With two years of handling pandemic under their belts, technology’s strategic importance as a business transformer has evolved, rather than just being a commodity service provider or a strategic business partner.

Read more


Values and Purpose

All our sustainability initiatives originate from and are driven by our corporate purpose of ‘Doing Well and Doing Good’. This purpose is embodied in our constant endeavour to make a positive difference by serving people and living our values. We stay true to our purpose by following three basic tenets:

Serving people
Making a positive difference
Living our value
Read more


Piramal Enterprises Limited was ranked 12th with an A+ Rating in “BW Businessworld India’s Most Sustainable Companies” (April 2022)

Piramal Pharma Solutions was awarded “2021 Global Contract Development and Manufacturing Organization Customer Value Leadership Award” by Frost & Sullivan at its “2021 MEASA Best Practices Awards” (October 2021)

Piramal Pharma Solutions was winner in “6 categories across small pharma” at “CMO Awards 2022” (March 2022)

Read more